|
FORM 4
[ ] Check this box if no longer
subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response. . . . . 0.5 |
|
1. Name and Address of Reporting Person*
Johnson, Jr., Franklin P.
(Last) (First) (Middle)
One Amgen Center Drive
(Street)
Thousand Oaks, CA 91320-1799
(City) (State) (Zip)
|
2. Issuer Name and Ticker or Trading Symbol AMGEN INC.
(AMGN) 3. I.R.S. Identification
Number of Reporting Person, if an entity (voluntary) |
4. Statement for Month/Day/Year 12/16/2002
5. If Amendment, Date of Original (Month/Day/Year) |
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable) X Director
10% Owner
Officer (give title below)
Other (specify below)
Description
7. Individual or Joint/Group
Filing (Check Applicable Line) X Form filed by One Reporting Person
Form filed by More than One Reporting Person
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|||||||||||||||
|
1. Title of Security (Instr. 3) |
2.Transaction
Date (Month/Day/Year) |
2A. Deemed Execution Date, if any
(Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4, and 5) |
5. Amount of
Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) |
6. Owner-
ship Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of
Indirect Beneficial Ownership (Instr. 4) |
||||||||
|
Code
|
V
|
Amount
|
A/D
|
Price
|
|||||||||||
|
Common Stock
|
12/16/02
|
|
G
|
V
|
18,000
|
D
|
$0
|
|
D
|
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
7,500
|
D
|
$50.0508
|
|
D
|
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
5,000
|
D
|
$50.1222
|
|
D
|
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
7,500
|
D
|
$50.1751
|
|
D
|
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
10,000
|
D
|
$50.4313
|
|
D
|
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
10,000
|
D
|
$50.152
|
1,053,129
|
D
|
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
7,500
|
D
|
$50.0508
|
|
I
|
By Partnership
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
5,000
|
D
|
$50.1222
|
|
I
|
By Partnership
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
10,000
|
D
|
$50.152
|
|
I
|
By Partnership
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
7,500
|
D
|
$50.1751
|
|
I
|
By Partnership
|
|||||
|
Common Stock
|
12/16/02
|
|
S
|
|
10,000
|
D
|
$50.4313
|
/1/ 1,324,744
|
I
|
By Partnership
|
|||||
|
Common Stock
|
12/16/02
|
|
G
|
V
|
18,000
|
D
|
$0
|
835,816
|
I
|
By Spouse
|
|||||
|
Contractual Contingent Payment Rights
|
|
|
|
|
|
|
|
/2/ 4
|
I
|
By Partnership
|
|||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|||||||||||||||
|
1. Title of Derivative Security
(Instr. 3) |
2. Conver-
sion or Exercise Price of Deri- vative Security |
3. Transaction Date
(Month/ Day/ Year) |
3A. Deemed Execution Date, if any
(Month/ Day/ Year) |
4. Transaction Code (Instr.8) |
5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable(DE) and
Expiration Date(ED) (Month/Day/Year) |
7. Title and Amount of
Underlying Securities (Instr. 3 and 4) |
8. Price
of Derivative Security (Instr.5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.4) |
10. Owner- ship Form of Deriv- ative Securities: Direct (D) or Indirect (I) (Instr.4) |
11. Nature of Indirect Beneficial Ownership (Instr.4) |
||||
|
Code
|
V
|
A
|
D
|
DE
|
ED
|
Title
|
Amount or Number of Shares
| ||||||||
| |
|
Name: Johnson, Jr., Franklin P Statement for Month/Day/Year: 12/16/2002
One Amgen Center Drive Issuer Name: Amgen Inc. (AMGN) Thousand Oaks, CA 91320-1799
Note: 2 (FPJ-CCPR) Contractual contingent payment rights arising from the purchase by Amgen, Inc. of two Class A interests of Amgen Clinial Partners, L.P. |
|
By: /s/ Lawrence M. Furst, Attorney-in-fact 12-16-02 ** Signature of Reporting Person Date SEC 1474 (9-02) |
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |